Perceptive Informatics
, an
eClinical
solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ:
PRXL
), today released an enhanced version of its comprehensive IMPACT®
clinical trial management system
(CTMS). Notable features include improved data entry as well as site management and monitoring capabilities. The system is designed for pharmaceutical and biotechnology companies of all sizes, and has more than 26,000 users in studies of up to tens of thousands of subjects and millions of visits.
According to market research firm MarketsandMarkets, the
CTMS
software industry is expected to jump from $567.2 million in 2010 to $1.3 billion by 2016.[1] Perceptive Informatics' CTMS solution provides a user-friendly infrastructure that enables clinicians to manage trials of varying complexity.
"Many top global pharmaceutical companies and CROs rely on the IMPACT CTMS solution to plan, administer and track every aspect of their clinical trials," said Nick Richards , Vice President, Product Management, Perceptive Informatics. "As clients face further globalization of clinical trials and require site management and monitoring of increasingly complex studies, they need technology that keeps pace. Perceptive's enhanced system represents a significant leap forward in flexibility and usability, enabling clients to improve the speed and effectiveness of their clinical development programs."
Perceptive's enhanced version is a customizable system which allows managers the flexibility to define which information is most important to their clinical trial and configure it accordingly. Highlights include:
Configurability by Clinical Trial Type
– Customers can define their own clinical trial types – from single-site investigator-initiated studies to large multi-country studies – enabling them to select the critical screens and fields that each requires. This simplifies and streamlines clinical trial management and ensures that users see exactly what they need.
Assistance for Field Monitors
– The IMPACT® MySites™ Module, which supports online and offline monitoring activities and the collection of associated management data, now enables contract research associates to record and manage contacts for the sites they monitor, allowing them to have a more comprehensive view of site activity.
Improved Data Mining Capabilities
– The IMPACT® Investigator Module's advanced search feature enables users to select physician names based on their location, specialty, therapeutic interests, responses to qualification questionnaires and investigator performance metrics in order to speed the finalization of candidate study sites and the recruitment of optimal investigators for a trial.
Perceptive Informatics' IMPACT CTMS solution is used to plan, track and report on clinical trials and is available as a hosted, software-as-a-service (
SaaS
) application. It is an integral part of the
Perceptive MyTrials
TM platform, which provides an application framework to converge its integrated suite of clinical trial software. For more information visit:
http://www.perceptive.com/ctms/impact
[1] MarketsandMarkets, "Clinical Trial Management Systems (CTMS) Market: Global Trends, Opportunities, Challenge and Forecasts (2011 - 2016)," January 2012.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.